Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial ; volume:202 ; number:1 ; day:14 ; month:8 ; year:2023 ; pages:57-65 ; date:11.2023
Breast cancer research and treatment ; 202, Heft 1 (14.8.2023), 57-65, 11.2023
- Urheber
-
Pádua Souza, Cristiano de
Carneiro, Ana Suellen Barroso
Oliveira Lessa, Ana Cecília de
Lacerda, Domício Carvalho
Paiva, Carlos Eduardo
Zorzetto, Marina Moreira Costa
Freitas, Ana Julia Aguiar de
Santana, Iara Viana Vidigal
Oliveira, Marco Antonio de
Palmero, Edenir Inêz
Marques, Márcia Maria Chiquitelli
Reinert, Tomás
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-023-07011-0
- URN
-
urn:nbn:de:101:1-2023112912510769874790
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pádua Souza, Cristiano de
- Carneiro, Ana Suellen Barroso
- Oliveira Lessa, Ana Cecília de
- Lacerda, Domício Carvalho
- Paiva, Carlos Eduardo
- Zorzetto, Marina Moreira Costa
- Freitas, Ana Julia Aguiar de
- Santana, Iara Viana Vidigal
- Oliveira, Marco Antonio de
- Palmero, Edenir Inêz
- Marques, Márcia Maria Chiquitelli
- Reinert, Tomás
- SpringerLink (Online service)
Ähnliche Objekte (12)
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy
Prediction of early clinical response to neoadjuvant chemotherapy in Triple-negative breast cancer: Incorporating Radiomics through breast MRI
A Brief Review of Treatment Options for Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer
Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy
Prediction of early clinical response to neoadjuvant chemotherapy in Triple-negative breast cancer: Incorporating Radiomics through breast MRI
A Brief Review of Treatment Options for Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer
Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy
Prediction of early clinical response to neoadjuvant chemotherapy in Triple-negative breast cancer: Incorporating Radiomics through breast MRI
A Brief Review of Treatment Options for Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer